Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Breast
| Protocol Number | NCT Number | Summary | Principal Investigator |
| NSABP B-51/RTOG 1304 | NCT01872975 | A study for women with early stage breast cancer to determine if giving less radiation is as effective as traditional radiation in patients who have had a very good response to chemotherapy received prior to surgery. | Grant Clark, MD |
| S1418/BR006 | NCT02954874 | For patients with high risk “triple negative” breast cancer, a study to see if using an immunotherapy (Pembrolizumab) after the usual treatments will help keep breast cancer from returning. | David Chism, MD |
|
For patients with HER 2 positive breast cancer receiving first line treatment for cancer that has spread to other parts of the body (metastatic). Study to see if adding Atezolizumab (immunotherapy) to a standard treatment regimen with Paclitaxel (chemotherapy), Trastuzumab (monoclonal antibody) and Pertuzumab (monoclonal antibody) will kill more tumor cells.
|
David Chism, MD |
COVID-19
| Protocol Number | NCT Number | Summary | Principal Investigator |
| NCICOVID-19 in Cancer Patients Study (N-CCaPS) |
A Longitudinal natural History Study for cancer patients receiving active treatment (current or within past 6 weeks) including adjuvant, Must have positive SARs CoV-2 test within 14 days.
|
David Chism, MD |
Gastrointestinal
| Protocol Number | NCT Number | Summary | Principal Investigator |
| A021502 | NCT02912559 | For patients with stage III colon cancer with deficient mismatch repair, to see if adding an immunotherapy (Atezolizumab) to the usual chemotherapy given after surgery will decrease the chance of cancer returning. | David Chism, MD |
| NRG-GI005 | NCT04068103 | For patients with resected stable Stage IIA Colon Cancer suitable for surveillance, testing the circulating tumor DNA as a predictive biomarker in Adjuvant chemotherapy. | David Chism, MD |
Genitourinary
| Protocol Number | NCT Number | Summary | Principal Investigator |
| NRG-GU005 | NCT03367702 | For patients with localized intermediate risk prostate cancer, testing short course radiation therapy versus standard radiotherapy. | Grant Clark, MD |
Gynecologic
| Protocol Number | NCT Number | Summary | Principal Investigator |
| NRG-GY005 | NCT02502266 | For patients with recurrent platinum resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer, to test the combination of cediranib and olaparib in comparison to each drug alone or other chemotherapy. | Brook Saunders, MD |
Leukemia/Lymphoma
| Protocol Number | NCT Number | Summary | Principal Investigator |
| AZA-MDS-006 (CONNECT) | NCT01688011 | For patients with new Leukemia and MDS, this study is gathering information about how patients feel when being treated for this cancer, what kind of medicine they are taking, and how their medicine is affecting them. | David Chism, MD |
Lung: Small Cell
| Protocol Number | NCT Number | Summary | Principal Investigator |
| NRG-CC003 | NCT02635009 | For patients with small cell lung cancer (limited and extensive stage), to test whether avoiding the hippocampus (part of the brain that is important for memory) during whole-brain radiation therapy prevents cognitive side effects. | Grant Clark, MD |
| NRG-LU005 | NCT03811002 | For patients with limited stage small cell lung cancer, to test usual chemoradiation therapy, versus chemoradiation therapy plus the addition of a new immunotherapy drug, Atezolzumab (MPDL3280A). | Grant Clark, MD |
Lung: Non-Small Cell
| Protocol Number | NCT Number | Summary | Principal Investigator |
| M19-700 | NCT04274907 | For patients with previously untreated NSCLC, with no prior treatment for Advanced or Metastatic disease, to study Venetoclax in combination with Pembrolizumab in patients whose tumors have high PD-L1 expression. | David Chism, MD |
Melanoma
| Protocol Number | NCT Number | Summary | Principal Investigator |
| DREAMseq EA6134 |
NCT02224781 | A study to determine which is the best sequence (targeted therapy followed by immunotherapy, or immunotherapy followed by targeted therapy) for treating patients with advanced BRAF positive melanoma. The medications include: Dabrafenib, Trametinib, Ipilimumab, and Nivolumab. | David Chism, MD |